Table 3 Clinical characteristics in responder and non-responder
| Â | Responder | Non-responder | p value |
|---|---|---|---|
Number | 13 | 13 | Â |
Initial dose (mg) | 8.9 ± 4.5 | 7.5 ± 2.7 | 0.56 |
Age (years) | 74.0 ± 12.0 | 76.0 ± 10.0 | 0.76 |
Sex (male, %) | 9 (69) | 6 (46) | 0.23 |
BMI (kg/m2) | 23.5 ± 3.8 | 24.1 ± 5.1 | 0.64 |
Previous HF hospitalization | 2.5 | 1.7 | 0.35 |
Etiology of heart failure | |||
Ischemic heart disease | 3 (23) | 5 (38) | 0.70 |
Dilated cardiomyopathy | 2 (15) | 3 (23) | Â |
Valvular heart disease | 3 (23) | 2 (15) | Â |
Others | 5 (38) | 3 (23) | Â |
Comorbid disease | |||
Hypertension | 9 (69) | 11 (85) | 0.35 |
Diabetes mellitus | 6 (46) | 8 (62) | 0.43 |
Dyslipidemia | 3 (23) | 7 (54) | 0.10 |
Atrial fibrillation | 10 (69) | 9 (77) | 0.69 |
Vital sign on admission | |||
Heart rate (bpm) | 77 ± 11 | 80 ± 24 | 0.74 |
SBP (mmHg) | 117 ± 23 | 129 ± 29 | 0.28 |
DBP (mmHg) | 71 ± 15 | 72 ± 19 | 0.76 |
Blood chemistry on admission | |||
Hemoglobin (g/dl) | 10.6 ± 2.5 | 10.0 ± 1.7 | 0.72 |
BUN (mg/dl) | 42.0 ± 26.0 | 54.0 ± 29.0 | 0.23 |
Scr (mg/dl) | 1.9 ± 1.0 | 2.1 ± 1.0 | 0.59 |
eGFR (ml/min/1.73 m2) | 32.8 ± 17.3 | 28.6 ± 18.3 | 0.54 |
Na (mEq/l) | 136.0 ± 6.0 | 138.0 ± 5.0 | 0.34 |
K (mEq/l) | 4.3 ± 1.2 | 4.3 ± 0.6 | 0.37 |
BNP (pg/ml) | 475 (151–1106) | 917 (484–1766) | 0.07 |
Medication on admission | |||
β-blockers | 8 (62) | 10 (77) | 0.42 |
RAS inhibitors | 10 (77) | 10 (77) | 1.00 |
Loop diuretics | 13 (100) | 13 (100) | 1.00 |
Thiazide diuretics | 6 (46) | 2 (15) | 0.10 |
Aldosterone antagonists | 8 (62) | 6 (46) | 0.46 |
Device therapy | 3 (23) | 4 (31) | 0.69 |